suit-in-crowd
19 February 2014Big Pharma

SPCs: a call for clarity

Supplementary protection certificates (SPCs) are national rights in Europe that extend patent protection for medicinal and plant protection products. Their aim is to compensate patentees for the years of patent term lost during lengthy regulatory approval processes that are necessary to get such products to market. Given that up to five-and-a-half years of additional protection can be gained beyond patent expiry, SPCs are often hard fought over before patent offices and the courts.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
11 February 2026   Courts on both sides of the Atlantic recorded a flurry of settlements this week, as Astellas, GSK, and Alexion drew a line under long-running disputes with generic rivals.
Big Pharma
27 November 2025   Clinical trials create a patent paradox. With EPO case law rapidly reshaping the 'expectation of success' test—most recently T136/24—the line between innovation and obviousness is blurred. Amanda Simons of J A Kemp offers drafting strategies to secure protection for your downstream innovations.
Big Pharma
20 November 2025   A new report from Clarivate highlights a jump in the tech’s adoption among IP professionals over the past two years, as well as concerns over governance.